3 assets in Chemotherapy-Induced Alopecia

Therapeutic assets addressing Chemotherapy-Induced Alopecia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Eribulin Chemotherapy-Induced Alopecia	Dana-Farber Cancer Institute	P2	CCC (53)
Minoxidil Chemotherapy-Induced Alopecia	Ohio State University Comprehensive Cancer Center	P2	CCC (53)
Trastuzumab Deruxtecan Chemotherapy-Induced Alopecia	Dana-Farber Cancer Institute	P2	CCC (53)